NCT05517564View on ClinicalTrials.gov

First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease

PHASE1UnknownINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

June 30, 2023

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

GM-60106

The participants will receive a single oral dose between 2.5 to 100 mg for Part A (SAD), Part B (MAD) once daily for 14 days, and for Part C (MAD) once daily for 28 days.

OTHER

Placebo

Placebo-to-match GM-60106 capsules

Trial Locations (2)

3004

Nucleus Network Pty Ltd, Melbourne

3220

Nucleus Network Pty Ltd, Geelong

Sponsors

Lead Sponsor

JD Bioscience Inc.
All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

JD Bioscience Inc.

INDUSTRY